Pingfu Fu Selected Research

Capromab Pendetide

9/2011	Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer.
4/2007	Rectal morbidity after permanent prostate brachytherapy with dose escalation to biologic target volumes identified by SPECT/CT fusion.
10/2003	Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma.
1/2003	Combination conformal radiotherapy and radioimmunoguided transperineal 103Pd implantation for patients with intermediate and unfavorable risk prostate adenocarcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pingfu Fu Research Topics

Disease

64	Neoplasms (Cancer) 10/2022 - 01/2003
25	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 01/2003
19	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2022 - 12/2005
11	Adenocarcinoma 07/2021 - 01/2003
9	Carcinogenesis 10/2017 - 05/2004
7	Breast Neoplasms (Breast Cancer) 10/2022 - 10/2007
7	Neoplasm Metastasis (Metastasis) 01/2018 - 05/2004
6	Inflammation (Inflammations) 09/2021 - 09/2006
6	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2021 - 06/2007
6	Lung Neoplasms (Lung Cancer) 11/2020 - 07/2008
5	Lymphoma (Lymphomas) 01/2020 - 01/2005
5	Disease Progression 04/2014 - 07/2004
4	Squamous Cell Carcinoma of Head and Neck 01/2022 - 11/2015
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 10/2007
4	Colonic Neoplasms (Colon Cancer) 01/2022 - 07/2008
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2009 - 01/2005
3	Multiple Myeloma 02/2021 - 08/2007
3	Adenocarcinoma of Lung 03/2019 - 07/2011
3	Pain (Aches) 06/2018 - 09/2009
3	Hematologic Neoplasms (Hematological Malignancy) 10/2017 - 04/2006
3	Mycosis Fungoides 01/2017 - 12/2010
3	Acquired Immunodeficiency Syndrome (AIDS) 06/2014 - 01/2005
3	Infections 06/2014 - 02/2004
3	Carcinoma (Carcinomatosis) 05/2013 - 01/2003
3	Graft vs Host Disease (Graft-Versus-Host Disease) 07/2011 - 02/2004
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2022 - 12/2020
2	Lymphopenia (Lymphocytopenia) 01/2022 - 08/2021
2	Prostatitis 09/2021 - 01/2003
2	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 01/2017 - 05/2012
2	Mesothelioma 03/2015 - 10/2014
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2013 - 05/2010

Drug/Important Bio-Agent (IBA)

16	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2003
14	Biomarkers (Surrogate Marker)IBA 11/2022 - 05/2009
8	ApigeninIBA 10/2015 - 12/2005
7	DNA (Deoxyribonucleic Acid)IBA 09/2021 - 07/2004
7	Biological ProductsIBA 11/2020 - 01/2003
6	Pharmaceutical PreparationsIBA 01/2022 - 07/2011
6	Docetaxel (Taxotere)FDA Link 01/2016 - 05/2009
5	Pemetrexed (MTA)FDA Link 01/2022 - 10/2013
5	Prostate-Specific Antigen (Semenogelase)IBA 09/2021 - 09/2006
5	Carmustine (FIVB)FDA Link 01/2017 - 01/2005
4	Immune Checkpoint InhibitorsIBA 06/2022 - 01/2020
4	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 01/2005
4	PlatinumIBA 01/2022 - 08/2014
4	Rituximab (Mabthera)FDA Link 01/2020 - 01/2006
4	ParaffinIBA 12/2018 - 01/2003
4	ErbB Receptors (EGF Receptor)IBA 01/2017 - 11/2009
4	Phosphotransferases (Kinase)IBA 10/2015 - 07/2011
4	Capromab Pendetide FDA Link 09/2011 - 01/2003
3	Eosine Yellowish-(YS) (Eosin)IBA 01/2022 - 11/2020
3	methoxyamineIBA 01/2021 - 11/2016
3	Histone Deacetylases (Histone Deacetylase)IBA 01/2019 - 12/2012
3	Messenger RNA (mRNA)IBA 01/2019 - 01/2003
3	Adenosine Monophosphate (AMP)IBA 01/2018 - 04/2013
3	fludarabineIBA 10/2017 - 10/2007
3	O(6)-benzylguanineIBA 01/2017 - 08/2007
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2017 - 11/2015
3	Sorafenib (BAY 43-9006)FDA Link 08/2014 - 05/2013
3	Etoposide (VP 16)FDA LinkGeneric 04/2014 - 01/2005
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2012 - 07/2004
3	rebeccamycinIBA 04/2012 - 12/2005
2	Complement System Proteins (Complement)IBA 01/2022 - 05/2021
2	durvalumabIBA 01/2022 - 01/2022
2	Hematoxylin (Haematoxylon)IBA 01/2022 - 07/2021
2	Peptides (Polypeptides)IBA 01/2021 - 04/2013
2	Temozolomide (Temodar)FDA LinkGeneric 01/2021 - 11/2012
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020 - 07/2009
2	thiamine triphosphorate (TTP)IBA 01/2020 - 03/2019
2	EnzymesIBA 01/2019 - 07/2008
2	Matrix Metalloproteinases (MMPs)IBA 01/2019 - 10/2007
2	Formaldehyde (Formol)FDA Link 12/2018 - 01/2018
2	Protein Kinases (Protein Kinase)IBA 01/2018 - 10/2014
2	Transcription Factors (Transcription Factor)IBA 09/2017 - 02/2014
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2017 - 11/2015
2	Alkyl and Aryl TransferasesIBA 01/2017 - 05/2012
2	Tyrosine Kinase InhibitorsIBA 11/2015 - 10/2013
2	Bevacizumab (Avastin)FDA Link 11/2015 - 05/2009
2	CreatinineIBA 11/2015 - 02/2008
2	Caspase 3 (Caspase-3)IBA 01/2015 - 12/2010
2	Small Interfering RNA (siRNA)IBA 10/2014 - 07/2007
2	Carboplatin (JM8)FDA LinkGeneric 08/2014 - 10/2007
2	AndrogensIBA 05/2014 - 12/2005
2	Antineoplastic Agents (Antineoplastics)IBA 05/2014 - 12/2012
2	AntigensIBA 07/2013 - 02/2004
2	Cadherins (E-Cadherin)IBA 01/2013 - 07/2007
2	flavoneIBA 12/2012 - 07/2007
2	Insulin-Like Growth Factor I (IGF-1)IBA 06/2012 - 12/2005
2	Insulin-Like Growth Factor Binding Protein 3IBA 06/2012 - 12/2005

Therapy/Procedure

26	Therapeutics 05/2022 - 12/2005
23	Drug Therapy (Chemotherapy) 10/2022 - 01/2005
10	Radiotherapy 01/2022 - 01/2003
7	Prostatectomy (Retropubic Prostatectomy) 01/2022 - 01/2018
6	Cell Transplantation 01/2022 - 01/2006
5	Brachytherapy 09/2013 - 01/2003
4	Immunotherapy 01/2022 - 10/2013
3	Adjuvant Chemotherapy 07/2021 - 01/2020
2	Adjuvant Radiotherapy 01/2022 - 08/2021
2	Music Therapy 06/2018 - 08/2017
2	Castration 01/2018 - 10/2014
2	Autologous Transplantation 10/2016 - 01/2005